Showing 981-990 of 1498 results for "".
- Read Their Lips: Avoid Unnatural Lip Enhancement Results With This Datahttps://modernaesthetics.com/news/read-their-lips-avoid-unnatural-lip-enhancement-results-with-this-data/2472247/Many a Real Housewife from Bravo’s hit reality TV franchise have been chastised for trout pout – or an overfilled, unnatural looking pucker. And now a new study, published by JAMA Facial
- Aesthetics Wire Exclusive: AAFPRS Survey Shows Combination Facial Plastic Surgery Treatment Requests Are Soaringhttps://modernaesthetics.com/news/aesthetics-wire-exclusivecombination-facial-plastic-surgery-treatment-requests-soaring/2472289/Combination therapies reign supreme, according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) 2016 statistics. In 2016, 66 percent of facial plastic surgeons reported performing combined non-surgical procedures in the same
- AAD Selects ContextMedia:Health as Patient Education Affinity Partnerhttps://modernaesthetics.com/news/aad-selects-contextmediahealth-as-patient-education-affinity-partner/2472318/ContextMedia:Health is now an Affinity Partner with the American Academy of Dermatology (AAD). The partnership offers ContextMedia:Health's suite of digital technology to the AAD's U.S. members at no cost. The agreement also bring
- Alma Launches AI-Assisted Skincare System with Nearly 12M Formulation Optionshttps://modernaesthetics.com/news/alma-launches-ai-assisted-skincare-system-with-nearly-12m-formulation-options/2475858/Alma has launched Universkin by Alma, a new AI-assisted medical-grade skincare platform designed to support physicians in offering personalized treatment regimens. The system enables rapid clinical assessment and tailored formulation of topical therapies using an intelligent diagnostic algorithm
- Obagi Medical Acquires Novaestiq to Introduce HA Injectables in US Markethttps://modernaesthetics.com/news/obagi-medical-acquires-novaestiq-to-introduce-ha-injectables-in-us-market/2475814/Obagi Medical is set to expand into aesthetic injectables following the acquisition of Novaestiq Corp., the company behind the Saypha® ChIQ™ and Saypha® MagIQ™ hyaluronic acid (HA) filler products. The transaction was completed by Obagi’s parent company, Waldencast
- Global Botulinum Toxins Market Projected to Reach $15.7 Billion by 2030https://modernaesthetics.com/news/global-botulinum-toxins-market-projected-to-reach-157-billion-by-2030/2475785/The global market for botulinum toxin products is expected to grow from $8.9 billion in 2025 to $15.7 billion by 2030, according to new projections from MarketsandMarkets, representing a compound annual growth rate (CAGR) of 11.7%. This sustained growth is attributed to increased global de
- CollPlant Appoints Bowman Bagley to Lead North American Commercial Operationshttps://modernaesthetics.com/news/collplant-appoints-bowman-bagley-to-lead-north-american-commercial-operations/2475724/CollPlant Biotechnologies has appointed Bowman Bagley as Vice President, Commercial North America, a newly established role aimed at expanding the company’s commercial presence and operations in the region. Bagley will oversee sales, marketing, lo
- The Aesthetic Society Unveils Redesigned Academy for On-Demand Learninghttps://modernaesthetics.com/news/the-aesthetic-society-unveils-redesigned-academy-for-on-demand-learning/2475683/The Aesthetic Society announced the launch of a redesigned interface for The Aesthetic Society Academy, its educational hub for plastic surgeons, aesthetic professionals, residents, and fellows. Available exclusively to Aesthetic Society and Allie
- Study: CINDR of Masseter Muscle Optimal Injection Site for Botoxhttps://modernaesthetics.com/news/study-cindr-of-masseter-muscle-optimal-injection-site-for-botox/2475664/Research published in the Annals of Anatomy journal indicates the center of the intramuscular nerve dense region (CINDR) of the masseter muscle as the optimal botulinum neurotoxin A (BoNT-A) injection site. The researchers used 60 rabbits to assess BoNT-A injection efficacy at the CINDR.<
- LevEllis Launches Regenerative Serum Featuring Skin-Specific Secretome Technologyhttps://modernaesthetics.com/news/levellis-launches-regenerative-serum-featuring-skin-specific-secretome-technology/2475660/LevEllis, Inc. announced the launch of PROVOQUE™, a physician-dispensed regenerative skincare serum formulated with a proprietary skin-specific secretome. Developed by surgeon and molecular biologist Laura Ellis, MD, the product represents a new approach in medical-grade skincare by delivering a